
Tevard Reports Data on Suppressor tRNA Therapy Restoring Full-Length Dystrophin in Duchenne Muscular Dystrophy Model
-Promising Study Results Featured During Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting- Boston, MA — Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, presented preclinical data demonstrating the potential of its tRNA therapy in Duchenne Muscular Dystrophy […]
Leer Más